Jessica L. Bloom

Jessica L. Bloom

Auto-generated profile, based on publicly available information

Jessica L. Bloom

University of Colorado Anschutz Medical Campus, Department of Pediatrics, Section of Rheumatology, Aurora, Colorado, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2017 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
JBJessica L. Bloom
Jessica L. Bloom
CLClara Lin
Clara Lin
LILisa Imundo
Lisa Imundo
SGStephen Guthery
Stephen Guthery
SSShelly Stepenaskie
Shelly Stepenaskie
JBJohn F. Bohnsack
John F. Bohnsack
H Syndrome is an autosomal recessive disorder characterized by cutaneous hyperpigmentation, hypertrichosis, and induration with numerous systemic manifestations. The syndrome is caused by mutations in SLC29A3, a gene located on chromosome 10q23, which encodes the human equilibrative transporter 3 (hENT3). Less than 100 patients with H syndrome have been described in the literature, with the majority being of Arab descent, and only a few from North America. Here we report five pediatric patients from three medical centers in the United States who were identified to have H syndrome by whole exome sequencing. These five patients, all of whom presented to pediatric rheumatologists prior to diagnosis, include two of Northern European descent, bringing the total number of Caucasian patients described to three. The patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis. They share genetic mutations previously described in patients of the same ethnic background, as well as a novel mutation. In two patients, treatment with prednisone improved inflammation, however both patients flared once prednisone was tapered. In one of these patients, treatment with tocilizumab alone resulted in marked improvement in systemic inflammation and growth. The other had partial response to prednisone, azathioprine, and TNF inhibition; thus, his anti-TNF biologic was recently switched to tocilizumab due to persistent polyarthritis. Another patient improved on Methotrexate, with further improvement after the addition of tocilizumab. H syndrome is a rare autoinflammatory syndrome with pleiotropic manifestations that affect multiple organ systems and is often mistaken for other conditions. Rheumatologists should be aware of this syndrome and its association with arthritis. It should be considered in patients with short stature and systemic inflammation, particularly with cutaneous findings. Some patients respond to treatment with biologics alone or in combination with other immune suppressants; in particular, treatment of systemic inflammation with IL-6 blockade appears to be promising. Overall, better identification and understanding of the pathophysiology may help devise earlier diagnosis and better treatment strategies.

5 October 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
JBJessica L. Bloom
Jessica L. Bloom
KPKaci Pickett‐Nairn
Kaci Pickett‐Nairn
LSLori Silveira
Lori Silveira
RFRobert C. Fuhlbrigge
Robert C. Fuhlbrigge
DCDavid Cuthbertson
David Cuthbertson
FCfor the Vasculitis Clinical Research Consortium
for the Vasculitis Clinical Research Consortium

17 July 2021 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
JBJessica L. Bloom
Jessica L. Bloom
BFBenjamin Frank
Benjamin Frank
JWJason P. Weinman
Jason P. Weinman
CGCsaba Galambos
Csaba Galambos
SOSean T. O’Leary
Sean T. O’Leary
RFRobert C. Fuhlbrigge
Robert C. Fuhlbrigge
Background: Respiratory conditions are the leading cause of hospitalization and death in children with Trisomy 21 (T21). Diffuse alveolar hemorrhage (DAH) occurs at higher frequency in children with T21; yet, it is not widely studied nor is there a standardized approach to diagnosis or management. The objective of this study was to identify children with T21 and DAH in order to understand contributing factors and identify opportunities to improve outcomes. We identified 5 children with T21 at a single institution with histology-proven DAH over 10 years and discuss their presentation, evaluation, management, and outcomes. We also reviewed the cases in the literature. Case presentation: Patient 1 died at age seven due to secondary hemophagocytic lymphohistiocytosis. DAH was seen on autopsy. Patient 2 was a three-year-old with systemic-onset juvenile idiopathic arthritis diagnosed with DAH after presenting for hypoxia. Patient 3 was diagnosed with DAH at age nine after presenting with recurrent suspected pneumonia and aspiration. Patient 4 was diagnosed with DAH at age eight after presenting with pallor and fatigue. She had additional ICU admissions for DAH with infections. Patient 5 developed hemoptysis at age three and had recurrent DAH for 10 years. Four patients responded positively to immune-modulation such as intravenous immunoglobulin, glucocorticoids, and rituximab. Of the 19 patients identified in the literature, only one was from the United States. The majority had anemia, respiratory distress, autoantibodies, and recurrences. Very few patients had hemoptysis. Idiopathic pulmonary hemosiderosis was the most common diagnosis. Almost all received glucocorticoids with or without additional immunosuppression. The majority of our patients and those in the literature had positive auto-antibodies such as anti-neutrophil cytoplasmic antibodies and anti-nuclear antigen antibodies. Diagnostic clues included respiratory distress, hypoxia, anemia, recurrent pneumonia, and/or ground glass opacities on imaging. We identified four contributors to DAH: structural lung abnormalities, pulmonary arterial hypertension, infection/aspiration, and autoimmune disease/immune dysregulation. Conclusion: These cases demonstrate the need for an increased index of suspicion for DAH in children with T21, particularly given the low frequency of hemoptysis at presentation, enrich the understanding of risk factors, and highlight the favorable response to immunosuppressive therapies in this vulnerable population.

4 September 2018 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
JBJessica L. Bloom
Jessica L. Bloom
JDJeffrey R. Darst
Jeffrey R. Darst
LPLori Prok
Lori Prok
JSJennifer B. Soep
Jennifer B. Soep
Henoch-Schonlein Purpura (HSP) is one of the most common vasculitides of childhood, with 10–20 cases per 100,000 children. It frequently occurs following an infectious trigger and involves IgA and C3 deposition in small vessel walls. HSP is characterized by palpable purpura plus IgA deposition on biopsy, arthritis/arthralgia, renal involvement (hematuria and/or proteinuria), and/or abdominal pain. It is not generally recognized as a cause of dilated coronary arteries. We describe the first reported case of HSP presenting with dilated coronary arteries. This patient is a nine-year-old previously healthy Caucasian male who presented with 1 week of petechiae on his lower legs, knee and ankle arthritis, and abdominal pain without fever, consistent with HSP. An echocardiogram revealed coronary dilation, including the left main (5.32 mm, Z score + 4.25) and left anterior descending (LAD) (3.51 mm, Z score + 2.64) coronary arteries. He received high dose aspirin, IVIG, and infliximab with normalization of the LAD. Skin biopsy revealed leukocytoclastic vasculitis with positive IgA staining. He was Rhinovirus/Enterovirus positive with Group A Streptococcus on throat culture. Cardiac findings, while rare, can exist in HSP. Coronary dilation appeared to respond to our hospital protocol’s Kawasaki Disease (KD) therapy, possibly indicating an overlap in HSP and KD pathophysiology. This case, along with prior reports of dilated coronaries in systemic juvenile idiopathic arthritis (SJIA), highlights the importance of considering other sources of systemic inflammation, in addition to KD, when coronary dilation is identified. The appropriate therapy, follow-up, and prognosis for our patient are not clear, as further studies are needed to determine the natural course of these findings.

1 February 2021 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
DHDaniel M. Hinds
Daniel M. Hinds
JBJessica L. Bloom
Jessica L. Bloom
JCJennifer C. Cooper
Jennifer C. Cooper
CDCullen M. Dutmer
Cullen M. Dutmer
CGCsaba Galambos
Csaba Galambos
DLDeborah R. Liptzin
Deborah R. Liptzin

7 May 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
MPMegan Mariko Perron
Megan Mariko Perron
SZSonja I Ziniel
Sonja I Ziniel
MCMegan Curran
Megan Curran
JBJessica L Bloom
Jessica L Bloom
PVPatricia Vega-Fernandez
Patricia Vega-Fernandez
CLClara Lin
Clara Lin